These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36559326)

  • 1. Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes.
    Stingl JC; Radermacher J; Wozniak J; Viviani R
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
    Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
    Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
    Klotz U
    Clin Pharmacokinet; 2007; 46(4):271-9. PubMed ID: 17375979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC
    Blazy C; Ellingrod V; Ward K
    Front Pharmacol; 2022; 13():939313. PubMed ID: 35814245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.
    Goutelle S; Bourguignon L; Bleyzac N; Berry J; Clavel-Grabit F; Tod M
    AAPS J; 2013 Apr; 15(2):415-26. PubMed ID: 23319287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.
    Müller DJ; Kekin I; Kao AC; Brandl EJ
    Int Rev Psychiatry; 2013 Oct; 25(5):554-71. PubMed ID: 24151801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
    Probst-Schendzielorz K; Viviani R; Stingl JC
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
    Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
    Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations.
    Matura JM; Shea LA; Bankes VA
    Ir J Med Sci; 2022 Oct; 191(5):2357-2365. PubMed ID: 34734388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
    Zandvliet AS; Huitema AD; Copalu W; Yamada Y; Tamura T; Beijnen JH; Schellens JH
    Clin Cancer Res; 2007 May; 13(10):2970-6. PubMed ID: 17504998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M; Tybring G; Dahl ML; Lindh JD
    Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.
    Zubiaur P; Figueiredo-Tor L; Villapalos-García G; Soria-Chacartegui P; Navares-Gómez M; Novalbos J; Matas M; Calleja S; Mejía-Abril G; Román M; Ochoa D; Abad-Santos F
    Biomed Pharmacother; 2022 Nov; 155():113747. PubMed ID: 36162369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
    Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
    Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.